Log in
NASDAQ:TMDX

TransMedics Group Stock Forecast, Price & News

$15.74
-0.74 (-4.49 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$15.69
Now: $15.74
$16.92
50-Day Range
$16.37
MA: $17.62
$18.84
52-Week Range
$10.10
Now: $15.74
$25.30
Volume1.31 million shs
Average Volume167,699 shs
Market Capitalization$427.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83
TransMedics, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation. Its Organ Care System preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Its Organ Care System incudes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains organs in a near physiologic state and enables surgeons to perfuse and ventilate the organ between the donor and recipient sites; OCS Heart, a portable heart perfusion system that helps to maintain organs in a warm functioning state outside of the body; and OCS Liver, a portable perfusion and monitoring system that maintains organs in a near physiologic state. The company offers its products in the United States and internationally. TransMedics, Inc. is headquartered in Andover, Massachusetts. TransMedics, Inc. is a subsidiary of Transmedics Group, Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TMDX
CUSIPN/A
CIKN/A
Phone978-552-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.60 million
Book Value$2.58 per share

Profitability

Net Income$-33,550,000.00
Net Margins-143.93%

Miscellaneous

EmployeesN/A
Market Cap$427.42 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$15.74
-0.74 (-4.49 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TMDX News and Ratings via Email

Sign-up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions

How has TransMedics Group's stock price been impacted by COVID-19?

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TMDX shares have increased by 15.6% and is now trading at $15.74.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of TransMedics Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for TransMedics Group
.

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for TransMedics Group
.

How were TransMedics Group's earnings last quarter?

TransMedics Group Inc (NASDAQ:TMDX) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.06. The company earned $3.39 million during the quarter, compared to analysts' expectations of $3.24 million. TransMedics Group had a negative return on equity of 49.98% and a negative net margin of 143.93%.
View TransMedics Group's earnings history
.

What price target have analysts set for TMDX?

4 Wall Street analysts have issued 12-month price targets for TransMedics Group's shares. Their forecasts range from $18.00 to $28.00. On average, they expect TransMedics Group's share price to reach $22.75 in the next twelve months. This suggests a possible upside of 44.5% from the stock's current price.
View analysts' price targets for TransMedics Group
.

Who are some of TransMedics Group's key competitors?

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Roku (ROKU), Gilead Sciences (GILD), AbbVie (ABBV), Advanced Micro Devices (AMD), Beyond Meat (BYND), Walt Disney (DIS), Guardant Health (GH), IBM (IBM), NVIDIA (NVDA) and AT&T (T).

Who are TransMedics Group's key executives?

TransMedics Group's management team includes the following people:
  • Dr. Waleed H. Hassanein, Pres, CEO & Director (Age 51)
  • Mr. Stephen Gordon, CFO, Treasurer & Sec. (Age 51)
  • Mr. John F. Carey, VP of Operations (Age 55)
  • Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 48)
  • Mr. Brian Thomson, VP of HR (Age 51)

When did TransMedics Group IPO?

(TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (14.55%), Federated Hermes Inc. (7.17%), Emerald Advisers LLC (3.13%), Emerald Mutual Fund Advisers Trust (2.85%), Bellevue Group AG (1.57%) and Macquarie Group Ltd. (1.80%). Company insiders that own TransMedics Group stock include David Weill, Edwin M Kania Jr, John F Carey, Stephen Gordon and Tamer I Khayal.
View institutional ownership trends for TransMedics Group
.

Which institutional investors are selling TransMedics Group stock?

TMDX stock was sold by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, Taylor Wealth Management Partners, Envestnet Asset Management Inc., UBS Group AG, and Advisor Group Holdings Inc.. Company insiders that have sold TransMedics Group company stock in the last year include John F Carey, Stephen Gordon, and Tamer I Khayal.
View insider buying and selling activity for TransMedics Group
.

Which institutional investors are buying TransMedics Group stock?

TMDX stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., FMR LLC, Bellevue Group AG, Macquarie Group Ltd., Emerald Advisers LLC, Alyeska Investment Group L.P., Emerald Mutual Fund Advisers Trust, and Monashee Investment Management LLC. Company insiders that have bought TransMedics Group stock in the last two years include David Weill, and Edwin M Kania Jr.
View insider buying and selling activity for TransMedics Group
.

How do I buy shares of TransMedics Group?

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $15.74.

How big of a company is TransMedics Group?

TransMedics Group has a market capitalization of $427.42 million and generates $23.60 million in revenue each year. The company earns $-33,550,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

What is TransMedics Group's official website?

The official website for TransMedics Group is www.transmedics.com.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.